Which statement correctly describes the roles of 503A and 503B in compounding under the FDCA?

• A. 503A governs outsourcing facilities; 503B governs traditional patient-specific compounding
• B. 503A and 503B both govern outsourcing facilities
• C. 503A governs labeling for biologics; 503B governs manufacturing of devices
• D. 503A governs traditional patient-specific compounding; 503B governs outsourcing facilities; both under FDCA

Answer: (D)

Two pathways exist under the FDCA for compounding: patient-specific traditional compounding and compounding by outsourcing facilities. Traditional, patient-specific compounding is governed by the provisions that define what can be prepared for an individual patient under a prescription and kept under the oversight of a licensed pharmacist and the state board of pharmacy. This route is treated more like pharmacy practice than manufacturing and enjoys certain exemptions from some FDA drug approval and manufacturing requirements, as long as it’s done in compliance with state laws and not on a large-scale or across-state commercial basis.

Outsourcing facilities, on the other hand, are a separate category created by the FDCA. These facilities compound sterile drugs in bulk and distribute them to healthcare facilities, often across state lines. They must register with the FDA and operate under current good manufacturing practices, with FDA oversight and inspections. They are not tied to a patient-specific prescription for a single individual.

So the statement that matches the FDCA roles is that traditional patient-specific compounding falls under the 503A framework, while outsourcing facilities fall under the 503B framework, with both pathways existing under the broader FDCA.